2019 No. 2

2019 Vol. 35, No. 2

Cover Content

Previous Issue | Next Issue

Select articles

Display Method:

Editorial

Current status and research interests of the diagnosis and treatment of cholestatic liver disease

Yu YueCheng, Chen ChengWei

2019, 35(2): 241-246. DOI: 10.3969/j.issn.1001-5256.2019.02.001

Abstract(2310)

PDF (2155KB)(617)

Abstract:

Cholestatic liver disease ( CSLD) is a group of liver diseases which can cause cholestasis and has a complex etiology. Its pathogenesis remains unclear, and there are still no effective treatment measures. In the recent decade, new achievements have been made on various aspects of CSLD, which provid...

Discussions by experts

Pathogenesis of cholestasis-induced liver fibrosis and thoughts for blockade

Chen RuiLing, Ma Xiong

2019, 35(2): 247-251. DOI: 10.3969/j.issn.1001-5256.2019.02.002

Abstract(2312)

PDF (1845KB)(563)

Abstract:

Cholestasis refers to a pathological state of disorders in the formation, secretion, and excretion of bile flow, and liver fibrosis is a process of tissue repair induced by liver injury. Cholestatic liver disease is a chronic liver disease caused by cholestasis, progressive bile duct injury, and per...

Current status of the pathogenesis, diagnosis, and treatment of drug-induced cholestasis

Liu Meng, Yang XuanZi, Yu LeCheng

2019, 35(2): 252-257. DOI: 10.3969/j.issn.1001-5256.2019.02.003

Abstract(2534)

PDF (2048KB)(575)

Abstract:

Drug-induced cholestasis ( DRIC) mainly includes cholestasis-type and mixed-type drug-induced liver injury ( DILI) . The Roussel Uclaf Causality Assessment Method scale should be used to determine the causality between drug and cholestasis and other etiologies should be excluded. Liver biopsy may he...

Pathogenesis and management strategies of liver failure-associated cholestasis

Mao Qing

2019, 35(2): 258-261. DOI: 10.3969/j.issn.1001-5256.2019.02.004

Abstract(2271)

PDF (1828KB)(478)

Abstract:

Liver failure is severe liver injury caused by a variety of factors. Liver failure-associated cholestasis is serious hepatocellular intrahepatic cholestasis with massive hepatocyte necrosis, which manifests as rapid increases in both conjugated and unconjugated bilirubin, and the level of bilirubin ...

New therapeutic targets and drugs for cholestatic liver disease

Guo MengMeng, Xie Wen

2019, 35(2): 262-265. DOI: 10.3969/j.issn.1001-5256.2019.02.005

Abstract(2072)

PDF (2003KB)(524)

Abstract:

Cholestatic liver disease is caused by the damage of bile duct cells and hepatocytes due to bile duct injury, accumulation of bile acids, and persistent inflammation. If it is not treated in time, cholestasis can lead to liver fibrosis, liver cirrhosis, and even end-stage liver disease. Primary bili...

Rationality of medication based on the “ascending” pathophysiology of cholestatic liver disease

Gu TianYi, Lu LunGen

2019, 35(2): 266-269. DOI: 10.3969/j.issn.1001-5256.2019.02.006

Abstract(1828)

PDF (1832KB)(446)

Abstract:

In recent years, some scholars have put forward the“ascending”pathophysiology of cholestatic liver disease, especially in primary biliary cholangitis ( PBC) and primary sclerosing cholangitis ( PSC) . According to this theory, cholestatic liver disease develops from the bottom to the top of the anat...

The role of enterohepatic circulation of bile acids and intestinal microbiota in the pathogenesis and treatment of cholestatic liver disease

Jia HaoYu, Yang ZhangQing

2019, 35(2): 270-274. DOI: 10.3969/j.issn.1001-5256.2019.02.007

Abstract(2529)

PDF (1841KB)(572)

Abstract:

Cholestatic liver disease refers to a liver disorder caused by cholestasis, which arise from a series of etiologies such as viruses, bacteria, parasites, drugs, poisons, autoimmunity, alcohol, stones, tumors, genetics, and metabolism. This disease has the main manifestations of a change in bile flow...

Therapeutic guidelines

The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma (2018)

Organ Transplantation Branch, Chinese Medical Doctor Association, Chinese Society of Organ Transplantation, Chinese Medical Association

2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008

Abstract(873)

PDF (261KB)(1609)

Abstract:

Diagnosis, management, and treatment of pancreatic adenocarcinoma (V2018)

National Health Commission of the People’s Republic of China

2019, 35(2): 281-293. DOI: 10.3969/j.issn.1001-5256.2019.02.009

Abstract(446)

PDF (564KB)(1386)

Abstract:

Standards for the diagnosis and treatment of pancreatic exocrine insufficiency (2018, Guangzhou)

Special Committee on Chronic Pancreatitis, Pancreatic Disease Specialized Committee, Chinese Medical Doctor Association

2019, 35(2): 294-298. DOI: 10.3969/j.issn.1001-5256.2019.02.010

Abstract(770)

PDF (267KB)(374)

Abstract:

Expert consensus on image-guided irreversible electroporation ablation for pancreatic cancer (2018)

Chinese Society of Interventional and Minimally Invasive Therapy, China Medicine Education Association

2019, 35(2): 299-302. DOI: 10.3969/j.issn.1001-5256.2019.02.011

Abstract(2128)

PDF (1840KB)(463)

Abstract:

An excerpt of International Liver Transplantation Society Asian consensus on the management of hepatitis C virus infection in resource limited setting—From noncirrhotic to decompensated disease and following liver transplantation

Shang LanLan, Chen XiaoYing, Li JunFeng, Chen Hong

2019, 35(2): 303-308. DOI: 10.3969/j.issn.1001-5256.2019.02.012

Abstract(339)

PDF (254KB)(105)

Abstract:

Original articles_Viral hepatitis

Clinical effect and safety of pegylated interferon-α-2a versus pegylated interferon-α-2b in treatment of chronic hepatitis B

Ji WeiJia, Yan XueBing

2019, 35(2): 309-314. DOI: 10.3969/j.issn.1001-5256.2019.02.013

Abstract(2545)

PDF (2027KB)(322)

Abstract:

Objective To investigate the clinical effect and safety of pegylated interferon-α-2 a ( PEG-IFN-α-2 a) versus pegylated interferon-α-2 b ( PEG-IFN-α-2 b) in the treatment of chronic hepatitis B ( CHB) . Methods The CHB patients who were treated with PEG-IFN-α-2 a ( 180 μg/week) or PEG-IFN-α-2 b ( 18...

Serum level of interferon-λ3 in patients with chronic hepatitis B and its clinical significance

Duan YuanLi, Guan ShiHe, Yang Kai, Chen LiWen, Zhang Hao, Wang Xiu, Pan ZhengLan, Hou ShuWen, Wang ZhaoFei

2019, 35(2): 315-318. DOI: 10.3969/j.issn.1001-5256.2019.02.014

Abstract(1748)

PDF (1974KB)(313)

Abstract:

Objective To investigate the serum level of interferon-λ3 ( IFN-λ3) and its clinical significance in patients with chronic hepatitis B ( CHB) , as well as its association with nucleos ( t) ide analogue ( NA) treatment. Methods A total of 119 CHB patients who were treated in The Second Affiliated Hos...

Influencing factors for hemolytic anemia in patients with chronic hepatitis C treated by ribavirin combined with pegylated interferon-α

Xu JinFeng, Zhang XiaoHui, Liu YaLi, Zhang Jing

2019, 35(2): 319-322. DOI: 10.3969/j.issn.1001-5256.2019.02.015

Abstract(1932)

PDF (1840KB)(299)

Abstract:

Objective To investigate the influencing factors for ribavirin ( RBV) -induced hemolytic anemia during the treatment of chronic hepatitis C using RBV combined with pegylated interferon-α ( PEG-IFNα) , and to provide a reference for early prediction of RBV-related hemolytic anemia in clinical practic...

The mRNA expression of TIPE2, Foxp3, and CTLA-4 in peripheral blood mononucleated cells in patients with chronic hepatitis C and their clinical significance

Kong Li, Jin Meng, Wang WeiZhen, Zhao SuXian, Wang ShanShan

2019, 35(2): 323-327. DOI: 10.3969/j.issn.1001-5256.2019.02.016

Abstract(1859)

PDF (2049KB)(295)

Abstract:

Objective To investigate the mRNA expression of tumor necrosis factor-alpha-induced protein 8-like 2 ( TIPE2) , Foxp3 ( a functional molecule for regulatory T cells) , and cytotoxic T-lymphocyte-associated antigen 4 ( CTLA-4) in peripheral blood mononuclear cells ( PBMCs) in patients with chronic he...

Original articles_Liver fibrosis and liver cirrhosis

Value of hepatitis B virus core-related antigen in predicting the natural course of chronic hepatitis B and liver fibrosis regression

Sun Chao, Chang XiuJuan, Li XiaoDong, Yang YongPing

2019, 35(2): 328-333. DOI: 10.3969/j.issn.1001-5256.2019.02.017

Abstract(1918)

PDF (1991KB)(399)

Abstract:

Objective To investigate the clinical value of hepatitis B virus core-related antigen ( HBcrAg) in predicting the natural course of chronic hepatitis B ( CHB) and liver fibrosis regression. Methods A total of 138 CHB patients who were admitted to 302 Hospital of PLA, The First Affiliated Hospital of...

Value of FibroScan combined with gamma-glutamyl transpeptidase-to-platelet ratio in predicting liver fibrosis in patients with chronic hepatitis B:A preliminary study

Huang ChunMing, Yang Zhan, Nie YuQiang, Hu ZhongWei, Zhou YongJian, Zhan YuanJing, Guo JiaWei, Yu WeiHua

2019, 35(2): 334-337. DOI: 10.3969/j.issn.1001-5256.2019.02.018

Abstract(2007)

PDF (1983KB)(318)

Abstract:

Objective To investigate the value of FibroScan combined with gamma-glutamyl transpeptidase-to-platelet ratio ( GPR) in predicting liver fibrosis stage in patients with chronic hepatitis B ( CHB) . Methods A total of 278 patients who were diagnosed with CHB by liver biopsy in Guangzhou Eighth People...

Influencing factors for FibroTouch measurements in chronic hepatitis B patients based on liver pathology

Li ZhengXin, Chen YangYi, Zhao ZhiMin, Lyu Jing, Chen GaoFeng, Liu ChengHai

2019, 35(2): 338-344. DOI: 10.3969/j.issn.1001-5256.2019.02.019

Abstract(1791)

PDF (2015KB)(297)

Abstract:

Objective To investigate the changes in positive staining of CD34, CK7, and CK19 and amount of fibrous collagen deposition in patients with chronic hepatitis B ( CHB) and the pathological basis affecting FibroTouch measurements. Methods A retrospective analysis was performed for the clinical data of...

Changes in procoagulant and anticoagulant factors in patients with hepatitis B cirrhosis

Deng YongDong, Peng XueBin, Yao LiQiong, Li Hai, Tan BangYun, Ma ChaoQun

2019, 35(2): 345-348. DOI: 10.3969/j.issn.1001-5256.2019.02.020

Abstract(1890)

PDF (1836KB)(291)

Abstract:
Objective To investigate the changes in procoagulant and anticoagulant factors and routine coagulation markers in patients with hepatitis B cirrhosis and their clinical significance. Methods A total of 105 patients with hepatitis B cirrhosis who were admitted to Department of Infectious Diseases in ...

Efficacy of transjugular intrahepatic portosystemic shunt versus endoscopic cyanoacrylate injection in treatment of gastric variceal bleeding: A meta-analysis

Li Jing, Jiang Yong, Zhang Xu

2019, 35(2): 349-353. DOI: 10.3969/j.issn.1001-5256.2019.02.021

Abstract(1877)

PDF (2003KB)(304)

Abstract:
Objective To evaluate the clinical efficacy and safety of transjugular intrahepatic portosystemic shunt ( TIPS) versus endoscopic cyanoacrylate injection in the treatment of gastric variceal bleeding through a meta-analysis. Methods Pub Med, Embase, the Cochrane Library, ScienceDirect, CNKI, and Wan...

Original articles_Others

Clinical features of autoimmune hepatitis and primary biliary cholangitis: A comparative analysis

Shu YanYun, Pan XiaoLi, Song YuHu, Ye Jin

2019, 35(2): 354-358. DOI: 10.3969/j.issn.1001-5256.2019.02.022

Abstract(2684)

PDF (1851KB)(371)

Abstract:

Objective To compare the clinical features of autoimmune hepatitis ( AIH) and primary biliary cholangitis ( PBC) , and to provide a reference for differentiation and early diagnosis of these two diseases. Methods A retrospective analysis was performed for the clinical data of 83 patients with AIH an...

Clinicopathological features of drug-induced liver injury or primary biliary cholangitis with vanishing bile duct syndrome

Ye LiHong, Wang ChongKui, Jin Peng, Zhao LiangLiang, Zhang HaiCong, Liu ZhiQuan, Tang YaFang

2019, 35(2): 359-363. DOI: 10.3969/j.issn.1001-5256.2019.02.023

Abstract(1921)

PDF (2162KB)(364)

Abstract:

Objective To investigate the clinical features of patients with drug-induced liver injury ( DILI) and vanishing bile duct syndrome ( VBDS) and patients with primary biliary cholangitis ( PBC) and VBDS. Methods A retrospective analysis was performed for the clinical data of 42 DILI patients and 43 PB...

Protective effect of hepatocyte growth-promoting factor against liver ischemia-reperfusion injury in rats and its mechanism of action

Luo YanQing, Feng ChunLin, Mei Yong, Du Chao, Ceng PengFei, Wang Jun, Wang GuoXing, Zhao Liang, Leng Kai

2019, 35(2): 364-367. DOI: 10.3969/j.issn.1001-5256.2019.02.024

Abstract(1671)

PDF (2194KB)(317)

Abstract:

Objective To investigate the protective effect of hepatocyte growth-promoting factor ( PHGF) against liver ischemia-reperfusion injury in rats and its mechanism of its action. Methods A total of 80 healthy male Sprague-Dawley rats were randomly divided into experimental group ( PHGF group) and contr...

Expression of Mindin, a pattern recognition molecule, in a mouse model of acute liver injury induced by carbon tetrachloride

Zhang Xin, Wang WenJun, Zhai Song, Li YaPing, Shi JuanJuan, Jia XiaoLi, Dang ShuangSuo

2019, 35(2): 368-371. DOI: 10.3969/j.issn.1001-5256.2019.02.025

Abstract(1770)

PDF (2111KB)(273)

Abstract:

Objective To investigate the dynamic expression of Mindin protein in mice with acute liver injury induced by carbon tetrachloride ( CCl4) and its mechanism of action. Methods A total of 48 male C57 B1/6 mice were selected and divided into experimental group ( n= 40) and control group ( n = 8) . The ...

Case reports

Neonatal intrahepatic cholestasis caused by Citrin deficiency with hepatic cirrhosis ascites as the main manifestation:A case report

Zhang JianLing, Shu SaiNan, Cai ZaiSheng, Luo XiaoPing, Dong Chen

2019, 35(2): 372-375. DOI: 10.3969/j.issn.1001-5256.2019.02.026

Abstract(1352)

PDF (2473KB)(373)

Abstract:

A case of arterio-biliary fistula during transjugular intrahepatic portosystemic shunt

Xi XiaoTan, Luo XueFeng, Zhu YongJun, Wang XiaoZe, Yang Li

2019, 35(2): 376-378. DOI: 10.3969/j.issn.1001-5256.2019.02.027

Abstract(1260)

PDF (1871KB)(291)

Abstract:

Primary biliary cholangitis-autoimmune hepatitis overlap syndrome with Wilson's disease: A case report

Pang XiangJun, Xin GuiJie, Zhang Juan, Yan Qi

2019, 35(2): 379-381. DOI: 10.3969/j.issn.1001-5256.2019.02.028

Abstract(1452)

PDF (1955KB)(293)

Abstract:

A case of acute hepatic venular occlusive disease caused by Gynura segetum

Qu WeiGe, Cai YanJun, Sun XiaoFeng, Qi Yue

2019, 35(2): 382-383. DOI: 10.3969/j.issn.1001-5256.2019.02.029

Abstract(1573)

PDF (1908KB)(325)

Abstract:

A case of Pneumocystis carini pneumonia after liver transplantation

Zhang DaLi, Gao YinJie, Feng DanNi, Zhang LiJuan, He Xi, Liu ZhenWen, Liu HongLing

2019, 35(2): 384-385. DOI: 10.3969/j.issn.1001-5256.2019.02.030

Abstract(1656)

PDF (1902KB)(308)

Abstract:

Glucocorticoid treatment of intrahepatic cholestasis caused by infectious cholangitis: A case report

Zhao YouYou, Zhang Duan, Yin Xin, Wen XiaoYu, Gao PuJun

2019, 35(2): 386-387. DOI: 10.3969/j.issn.1001-5256.2019.02.031

Abstract(1724)

PDF (2020KB)(323)

Abstract:

A case of IgG4-related autoimmune pancreatitis

Han Lin, Yu Fan, Qin ShaoYou, Zhou ZhangYu

2019, 35(2): 388-389. DOI: 10.3969/j.issn.1001-5256.2019.02.032

Abstract(1718)

PDF (1806KB)(334)

Abstract:

Child pancreatoblastoma: A case report and review of the literature

Wang Kun, Liu Feng, Abudureyimu Tuerhong, Yang Fan, Liu YaHui, Zhang Wei

2019, 35(2): 390-391. DOI: 10.3969/j.issn.1001-5256.2019.02.033

Abstract(1614)

PDF (1973KB)(325)

Abstract:

Primary pancreatic signet ring cell carcinoma: A case report and literature review

Zhang JiaQi, Yao XiaoXiao, Tian Xuan, Zhang LiFu, Fang He, Jia MingKu, Zhang Dan

2019, 35(2): 392-394. DOI: 10.3969/j.issn.1001-5256.2019.02.034

Abstract(840)

PDF (261KB)(130)

Abstract:

Reviews

Research advances in the role of lipid metabolism in hepatitis C virus infection and life cycle

Xu Chu, Zhang PingAn

2019, 35(2): 395-398. DOI: 10.3969/j.issn.1001-5256.2019.02.035

Abstract(1765)

PDF (1841KB)(315)

Abstract:
Hepatitis C virus ( HCV) infection is one of the leading causes of liver cirrhosis, end-stage liver disease, and even liver cancer. Patients with HCV infection tend to have insulin resistance and dyslipidemia, which may lead to a series of metabolic syndromes and greatly threaten human health. At pr...

Mechanism and current status of carvedilol in treatment of cirrhotic portal hypertension

He Bo, Zhang ChunQing

2019, 35(2): 399-401. DOI: 10.3969/j.issn.1001-5256.2019.02.036

Abstract(2737)

PDF (1824KB)(478)

Abstract:
The formation of cirrhotic portal hypertension depends on the increase in intrahepatic vascular resistance and the state of hyperdynamic circulation. The specific effect of carvedilol in reducing intrahepatic vascular resistance has a better effect in alleviating portal hypertension in theory. This ...

Mechanism and current status of simvastatin in treatment of cirrhotic portal hypertension

Wu Huan, Wu Long, Yang Jing

2019, 35(2): 402-405. DOI: 10.3969/j.issn.1001-5256.2019.02.037

Abstract(1879)

PDF (1841KB)(408)

Abstract:
Besides related etiologies, portal hypertension ( PHT) is considered an important physiological link in promoting liver dysfunction. Literature review has shown that compared with the conventional drugs for the prevention and treatment of PHT, simvastatin can induce the expression of Kruppel-like fa...

Noninvasive diagnosis of progressive nonalcoholic fatty liver disease

Gong Hang, Li LiangPing

2019, 35(2): 406-410. DOI: 10.3969/j.issn.1001-5256.2019.02.038

Abstract(2070)

PDF (1848KB)(350)

Abstract:
Nonalcoholic fatty liver disease ( NAFLD) is characterized by the pathological feature of hepatocyte fatty degeneration and lipid accumulation, and liver histopathology evolves from simple liver fatty degeneration to steatohepatitis with hepatocellular injury and finally progresses to liver fibrosis...

The association between interleukin-8 and autoimmune liver diseases

Lei YunJie, Yang JinHui

2019, 35(2): 411-413. DOI: 10.3969/j.issn.1001-5256.2019.02.039

Abstract(1922)

PDF (1826KB)(316)

Abstract:
Interleukin-8 ( IL-8) is an inflammatory cytokine with chemotaxis and there is a significant increase in the expression of IL-8 in autoimmune liver diseases. It participates in disease progression by binding to its receptors CXCR1 and CXCR2, promoting chemotaxis of inflammatory cells, angiogenesis, ...

Influencing factors for short-term prognosis of liver failure in pregnancy

Zhang BaoZhong, Zhou PengZhi

2019, 35(2): 414-418. DOI: 10.3969/j.issn.1001-5256.2019.02.040

Abstract(1322)

PDF (1846KB)(304)

Abstract:
Liver failure in pregnancy is one of the most serious complications that greatly threaten the safety of pregnant women and parturients, with a high mortality rate and poor prognosis. The short-term prognosis of liver failure in pregnancy can be predicted based on etiology, clinical type and stage of...

Clinical features of patients with liver failure and fungal infections and influencing factors for prognosis

Wang Yu, Hu JinHua

2019, 35(2): 419-423. DOI: 10.3969/j.issn.1001-5256.2019.02.041

Abstract(1634)

PDF (1849KB)(393)

Abstract:

Liver failure is severe liver injury due to a variety of causes and has complex and diverse complications. Fungal infection is one of the serious complications of liver failure which often occurs in the advanced stage of liver failure, greatly affects prognosis, and leads to a significant increase i...

Effect of various cells on the activation of hepatic stellate cells in liver microenvironment

Xu Ying, Zhang DingQi, Chen JiaMei, Liu Wei, Liu Ping

2019, 35(2): 424-430. DOI: 10.3969/j.issn.1001-5256.2019.02.042

Abstract(1841)

PDF (2080KB)(421)

Abstract:
Liver fibrosis is a dynamic pathological process characterized by excessive deposition of extracellular matrix ( ECM) or hyperplasia of scar tissue. The activation of hepatic stellate cells ( HSCs) is generally considered the central link in the formation of liver fibrosis. HSC activation is regulat...

Bile formation, secretion, and excretion and the pathogenesis of cholestasis

Shen Hong, Hu Meng, Wei ZeHui, Zhang Dong, Zhang JunChang, Tian GuangJun

2019, 35(2): 431-437. DOI: 10.3969/j.issn.1001-5256.2019.02.043

Abstract(2008)

PDF (292KB)(1312)

Abstract:
Normal bile formation, secretion, and excretion are important physiological processes in human body. Bile plays an important role in promoting lipid digestion and absorption, eliminating metabolic waste, and regulating cholesterol metabolism. Disorders in bile formation, secretion, or excretion due ...

Current status of clinical research on hematobilia

Ma Min, Zhou ZhongYin

2019, 35(2): 438-440. DOI: 10.3969/j.issn.1001-5256.2019.02.044

Abstract(705)

PDF (167KB)(188)

Abstract:
Hematobilia is one of the rare causes of upper gastrointestinal bleeding. It is difficult to diagnose in clinical practice, due to its atypical clinical manifestations, rare Quikle triad ( abdominal pain, jaundice, and upper gastrointestinal bleeding) , and a lack of specificity.At present, it is be...

Epidemiology of polypoid lesions of the gallbladder and related risk factors

Chen ShanPeng, Wang ZhiXiang, Zhang XiaoDi, Shen NaiYing, Wei ZhiLi

2019, 35(2): 441-443. DOI: 10.3969/j.issn.1001-5256.2019.02.045

Abstract(1885)

PDF (1817KB)(312)

Abstract:

Polypoid lesions of the gallbladder ( PLG) is a common gallbladder disease in clinical practice. Most patients have non-adenomatous polyps, while adenomatous polyps are observed in a small number of patients. This article summarizes the epidemiology of PLG and related risk factors and points out tha...

Establishment and application of animal models of cholestasis

Du LiNa, Yang Yan

2019, 35(2): 444-447. DOI: 10.3969/j.issn.1001-5256.2019.02.046

Abstract(1382)

PDF (199KB)(773)

Abstract:
Cholestatic liver disease is one of the common diseases in children aged < 1 year and has a complex etiology and different outcomes. Various animal models have been established to further investigate the pathogenesis of cholestatic liver disease and related treatment strategies. A model of obstru...

Research advances in the epidemiological features, pathogenesis, and diagnosis and treatment of alcoholic pancreatitis

Hu JiangFeng, Lu LunGen

2019, 35(2): 448-450. DOI: 10.3969/j.issn.1001-5256.2019.02.047

Abstract(1857)

PDF (1827KB)(409)

Abstract:
There has been a significant increase in the number of patients with alcoholic pancreatitis in recent years, and the pathogenesis of alcoholic pancreatitis is associated with various factors including genetic factors, smoking, and gut microbiota. Alcoholic pancreatitis is different from other types ...

Features of infection secondary to severe acute pancreatitis and related control strategies

Tian Hao, Li FuXing, Song ShaoWei

2019, 35(2): 451-456. DOI: 10.3969/j.issn.1001-5256.2019.02.048

Abstract(491)

PDF (259KB)(279)

Abstract:
Severe acute pancreatitis ( SAP) is an acute abdominal disease and a critical illness commonly seen in clinical practice. Infection complications in the middle and late stages of SAP have a great impact on the prognosis of SAP and are often difficult to avoid. This article introduces the pathogenesi...